| 摘要: |
| ［摘要］ 纵向研究高效抗逆转录病毒治疗(HAART)对HIV单一感染者和HIV/HCV合并感染者外周血单个核细胞（PBMCs）中粘病毒抵抗蛋白MxA mRNA表达水平的影响，分析HAART后HIV/HCV合并感染者抗HCV前基线MxA mRNA水平是否与后续干扰素抗HCV疗效有关。方法 以广州市第八人民医院收治的艾滋病患者（HIV单一感染组,HAART前CD4+ T淋巴细胞<200个/mm3,42例）和HIV/HCV合并感染患者(HIV/HCV合并感染组，HAART前CD4+ T淋巴细胞<200个/mm3,33例)为研究对象,并以22名健康自愿者作为对照；观察患者在抗HCV治疗前的HAART的不同时间点（0 W、4 W、12 W、24 W、48 W、72 W、96 W）PBMCs中MxA mRNA表达水平；对比分析后继抗HCV治疗效果（有早期病毒学应答EVR，无早期病毒学应答NEVR）与MxA mRNA表达水平的关系。结果 HIV单一感染组PBMCs中MxA mRNA水平在HAART 4 W后下降（P<0.05），其他各时间点及与健康对照组之间差异均无统计学意义(P>0.05)；HIV/HCV合并感染组PBMCs中HAART各时间点及与健康对照组之间差异均无统计学意义(P>0.05)；HAART 96 W后进行抗HCV治疗,EVR组抗HCV治疗前MxA mRNA水平较NEVR组高（P<0.05）。结论 长期HAART对HIV/HCV合并感染者PBMCs中MxA mRNA表达水平无显著影响；但HAART后抗HCV治疗前PBMCs中MxA mRNA水平可作为HIV/HCV合并感染者抗HCV疗效的预测指标之一。 |
| 关键词: 慢性丙型肝炎 人类免疫缺陷综合症 粘病毒抵抗蛋白A 早期病毒学应答 |
| DOI：10.3969/j.issn.1674-3806.2016.07.02 |
| 分类号:R 51 |
| 基金项目:广东省医学科研基金资助项目（编号：A2009498）；国家自然科学基金资助项目（编号：81201286）；“十二五”国家科技重大专项基金项目（编号：2012ZX10001003003）；广州市科信局科技惠民专项基金项目（编号：2014Y2-00149） |
|
| The effect of HAART on the expression of MxA in PBMCs of HIV/HCV co-infected patients and its relationship with the efficacy of subsequent anti-HCV |
|
GONG Lan, PAN Neng-lang, CHEN Zhen-yu, et al.
|
|
Department of Laboratory Medicine, the First People′s Hospital of Guangzhou, Guangdong 510080, China
|
| Abstract: |
| ［Abstract］ Objective To longitudinally study the effect of highly active anti-retroviral therapy(HAART) on the expression levele of antiviral protein MxA mRNA in peripheral blood mononuclear cells(PBMCs) of HIV mono-infected and HIV/HCV co-infected patients and to explore the relationship between the baseline of MxA mRNA level in HIV/HCV co-infected patients after HAART and the efficacy of subsequent anti-HCV with interferon.Methods Forty-two cases of HIV mono-infected patients and 33 cases of HIV/HCV co-infected patients were recruited as the objects of this study and 22 healthy volunteers were enrolled in the control group. All patients were collected from the Eighth People′s Hospital of Guangzhou, whose CD4+ T<200 cells/mm3 before HAART. Before anti-HCV therapy, the levels of MxA mRNA expression in PBMCs of HIV/HCV co-infected patients at different time points of HAART(0 W, 4 W, 12 W, 24 W, 48 W, 72 W, 96 W) were observed in this study. The relationship between the therapeutic effect of subsequent anti-HCV and MxA mRNA was analyzed. Early viral response(EVR) and non early viral response(NEVR) were used to evaluate the effect of ant-HCV in this study.Results The levels of MxA mRNA in the PBMCs of HIV mono-infected group were decreased 4 weeks after HAART(P<0.05), while there were no significant differences among the other time points of HAART in the same group and between the HIV mono-infected group and the control group(P>0.05). There were no significant differences in the HIV/HCV co-infected group in and between it and the control group among all time points(P>0.05). After the HAART of 96 weeks in anti-HCV therapy for HIV/HCV co-infected patients, the MxA mRNA levels before anti-HCV therapy were significantly higher in the EVR group than those in the NEVR group(P<0.05).Conclusion Long-term HAART has no significant effect on the expression levels of MxA mRNA in PBMCs of HIV/HCV co-infected patients, however, the levels of MxA mRNA after HAART and before anti-HCV therapy can be one of the predictors of anti-HCV effect for HIV/HCV co-infected patients. |
| Key words: Chronic hepatitis C AIDS Myxovirus resistance A Early viral response |
